Follow up of three cases after adjuvant treatment of high risk gastrointestinal stromal tumors with Imatinib [7]

Annals of Oncology

Volumn 18, Issue 6, 2007, Pages 1123-1125

  Armbrust, T ^a   Sobotta, M ^a   Ramadori, Gramado ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADJUVANT THERAPY; ADULT; AGED; BONE METASTASIS; CANCER STAGING; CANCER SURGERY; CASE REPORT; CODON; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; EXON; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LAPAROTOMY; LETTER; LIVER METASTASIS; MALE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 34447322299     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm266     Document Type: Letter

References (9)

1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. Gain-of-function mutations of c-Kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
2. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Hum Patnol 2001; 32: 578-582.
3. DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
4. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: Current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7: 705-712.
5. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.
6. Fletcher CDM, Berman JJ, Corless CL et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465.
7. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002; 38(suppl 5): S37-38.
8. DeMatteo RP, Antonescu CR, Chadaram V. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. J Clin Oncol 2005ASCO Ann Meet Proc. 23(suppl): 9009.
9. Lai IR, Hu RH, Chang KJ. Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors? Hepatogastroenterology 2005; 52: 826-828.